Curant Rare and Cencora Forge Alliance to Speed Up Rare Disease Cures

ATLANTA, GA – January 22, 2026 – Curant Rare and Cencora have announced a strategic collaboration designed to dismantle the significant barriers that delay or prevent rare and orphan drugs from reaching patients. The partnership aims to create an integrated, end-to-end commercialization pathway, combining Cencora's global logistics and market access muscle with Curant Rare's specialized, high-touch patient support services.

This initiative addresses a critical pain point in modern medicine. While scientific breakthroughs are delivering unprecedented hope for patients with rare conditions, the journey from lab to patient is fraught with logistical, regulatory, and financial hurdles that can stall even the most promising therapies.

The High Stakes of Rare Disease Commercialization

Bringing a rare disease drug to market is a uniquely challenging endeavor. Unlike treatments for common conditions, these therapies serve small, geographically dispersed patient populations, making traditional clinical trials and distribution models inefficient and costly. Pharmaceutical innovators face a gauntlet of obstacles that this new collaboration seeks to address directly.

Logistical complexity is a primary concern. A significant portion of new specialty medicines, including revolutionary cell and gene therapies for conditions like Spinal Muscular Atrophy (SMA), require strict temperature controls and rapid, secure delivery across international borders. A failure at any point in this cold chain can render a life-saving dose unusable. Cencora, formerly AmerisourceBergen, has been investing heavily in its infrastructure, including a $1 billion plan to modernize its US distribution network, to handle precisely these types of fragile, high-value products.

Regulatory pathways are another minefield. In Europe, for example, the upcoming EU Health Technology Assessment (HTA) regulation, set for full implementation for rare diseases in 2028, will create new demands for comparative evidence. Generating this evidence is notoriously difficult for rare conditions, where small patient numbers and disease heterogeneity often preclude large-scale randomized clinical trials. Developers are often forced to rely on observational studies and single-arm trials, which may not satisfy the rigorous demands of all assessment bodies.

Beyond logistics and regulation, market access presents a formidable barrier. Companies must develop sophisticated channel strategies to navigate a complex web of payers, physician specialists, and treatment settings—from specialized academic centers to local clinics. Securing reimbursement and helping patients overcome financial and insurance hurdles are critical steps that require deep expertise, which is a core component of the services being offered.

An Integrated Blueprint for a Fragmented Market

The Curant Rare-Cencora partnership is structured to function as a single, streamlined solution to this fragmented landscape. By knitting together their distinct but complementary capabilities, the two organizations offer pharmaceutical companies a unified partner to manage the entire commercialization lifecycle.

Cencora brings its formidable global infrastructure to the table. This includes its specialty logistics arm, World Courier, which handles complex global shipping, and its broad suite of commercialization services. These services provide crucial support in areas like pharmacovigilance, which involves monitoring a drug's effects after it has been licensed for use, and developing market access strategies to navigate payer requirements. Cencora's dedicated Orphan Drug Program is also a key asset, designed to help manufacturers manage the specific pricing and compliance requirements associated with the 340B drug pricing program in the United States.

On the other side of the collaboration, Curant Rare, a specialized business unit of Curant Health, provides the critical patient-facing component. With over two decades of experience, Curant Rare focuses on a personalized, high-touch care model through its proprietary Medication Care Management® services. This involves not just dispensing medication but providing comprehensive support to patients and their families, helping them navigate insurance authorizations, secure financial assistance, and adhere to complex treatment regimens. This patient-centric approach is designed to generate valuable real-world evidence and patient-reported outcomes, data that is increasingly vital for demonstrating a therapy's long-term value to payers and regulators.

“Our combined efforts focus on overcoming challenges in access and implementation,” said Patrick Dunham, CEO and Co-Founder of Curant Health, in the initial announcement. “The goal of this collaboration is to transform the way Rare and Orphan therapies are introduced to market, ensuring they reach the patients who need them most.”

From Pipeline to Patient: The Anticipated Impact

For the estimated 300 million people worldwide living with a rare disease, the most important metric is speed-to-therapy. By creating a more efficient commercialization pathway, the collaboration promises to shorten the timeline between a drug's approval and its availability to a patient in need. This integrated model aims to eliminate the delays that often occur when multiple, uncoordinated vendors handle different aspects of logistics, patient services, and market access.

For pharmaceutical and biotech companies, particularly smaller firms that may lack the internal infrastructure to manage a complex launch, this partnership offers a turnkey solution. It allows them to de-risk the commercialization process and accelerate market entry. Access to actionable insights from Curant Rare’s patient support programs can also provide a competitive advantage, helping companies refine their post-launch strategies and better articulate their product's value proposition with real-world data. This can lead to more favorable reimbursement decisions and a stronger market position.

The patient journey is also expected to be significantly optimized. Instead of navigating a confusing maze of providers, logistics companies, and support programs, patients and their caregivers can benefit from a more cohesive experience managed through Curant Rare's omnichannel engagement solutions. This personalized support system is designed to improve treatment adherence and, ultimately, enhance patient quality of life and health outcomes.

Navigating a Competitive and Evolving Landscape

The Curant Rare and Cencora initiative enters a dynamic and competitive market. The growing pipeline of specialty drugs has attracted a wide range of players, from other large pharmaceutical service providers like Cardinal Health to specialized CROs and technology firms, all vying to support the lucrative rare disease sector. Large integrated healthcare systems are also expanding their specialty capabilities, often through strategic acquisitions of physician networks and service providers.

However, the Curant-Cencora model seeks to differentiate itself through the depth of its integration. Rather than offering services à la carte, the collaboration presents a pre-built, comprehensive solution that spans the entire continuum from late-stage clinical logistics to long-term patient management. This synergy between Cencora's large-scale commercial infrastructure and Curant Rare’s bespoke, patient-level expertise is the partnership's core value proposition.

By combining global logistical power with personalized patient care, the alliance offers a compelling blueprint for the future of rare disease therapy delivery. It reflects a broader industry trend toward strategic partnerships designed to tackle complex healthcare challenges that no single entity can solve alone. The success of this model could set a new standard for how innovative medicines are brought to market, ensuring that scientific progress translates more rapidly into tangible benefits for patients with the greatest need.